KospicyKorean filings in English
Companies / Celltrion

Celltrion

(주)셀트리온

KOSPI · 068270KSIC 21100FY ends month 12Consolidated statementsMarket view
Revenue (TTM)
5,444.4 bn
Revenue growth
39.7%
Operating margin
32.6%
Net margin
24.4%
ROE
7.8%

Quarterly results

KRW bn2024 Q42025 Q12025 Q22025 Q32025 Q42026 Q12026 Q22026 Q3
Revenue1,063.6841.9961.51,029.01,330.21,145.01,393.71,575.5
Operating income196.4149.4242.5301.4475.2321.9451.8525.3
Net income235.6108.363.3331.9527.9349.8371.378.4
Cash from operations305.9113.4188.1204.6139.9238.2413.3217.0
Free cash flow262.984.4169.3182.8101.3203.1335.9154.3

Annual results

KRW bn202320242025
Revenue2,176.43,557.34,162.5
Operating income651.5492.01,168.5
Net income539.7418.91,031.5
Cash from operations537.2901.9646.1
Free cash flow327.1766.8537.8

Other ratios trailing 12 months

Gross margin61.7%
ROA6.0%
Liabilities / equity0.31x
Current ratio1.36x
FCF margin14.6%
CFO / net income0.76x

Recent filings

FilingForm
Mon 16 Nov 2026
Quarterly Report — 2026.0910-QDART
Fri 13 Nov 2026
Insider Ownership Report4EN form
Share Buyback Results8-KEN form
Mon 02 Nov 2026
Material Information for Investment Decisions — CTP13SC — Part1&2
투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 유럽 임상 3상 시험계획 승인(Part1&2) (류마티스 관절염 환자))
8-KEN
Fri 30 Oct 2026
Insider Ownership Report4DART
Insider Ownership Report4DART
Insider Ownership Report4DART
Insider Ownership Report4DART
Insider Ownership Report4DART
Tue 27 Oct 2026
[Amendment] Preliminary Consolidated Operating Results (Fair Disclosure)8-K/ADART
Beneficial Ownership Report (5%) — Standard FormSC 13D/GDART
Mon 26 Oct 2026
Material Event Report — Share Buyback Decision8-KEN
Thu 22 Oct 2026
Material Information for Investment Decisions
투자판단관련주요경영사항 (반감기 연장 기술이 적용된 장기 지속형 항APRIL 항체 Licensein 계약 체결)
8-KDART
Tue 20 Oct 2026
Share Buyback Results8-KDART
Wed 14 Oct 2026
Material Information for Investment Decisions — CTP13SC
투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 한국 임상 3상 시험계획 승인)
8-KDART
Mon 12 Oct 2026
Preliminary Consolidated Operating Results (Fair Disclosure)8-KDART
Tue 29 Sep 2026
Material Event Report — Share Buyback Decision8-KDART
Wed 23 Sep 2026
Material Information for Investment Decisions — CTP13SC
투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 미국 임상 3상 시험계획 승인)
8-KDART
Beneficial Ownership Report (5%) — Standard FormSC 13D/GDART
Mon 21 Sep 2026
Material Information for Investment Decisions — CTP44 — Part1&2
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 유럽 임상 3상 시험계획 변경신청 승인(Part1&2))
8-KDART
Wed 16 Sep 2026
Share Cancellation Decision8-KDART
Share Buyback Results8-KDART
Mon 07 Sep 2026
Material Information for Investment Decisions — CTP51
투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인)
8-KDART
Material Information for Investment Decisions — CTP44
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청 승인)
8-KDART
Mon 31 Aug 2026
Ad-hoc Disclosure Matters — Fair Disclosure8-KDART
Material Event Report — Share Buyback Decision8-KDART
Fri 28 Aug 2026
Beneficial Ownership Report (5%) — Standard FormSC 13D/GDART
Other Disclosure
대규모기업집단현황공시[분기별공시(개별회사용)]
OtherDART
Tue 25 Aug 2026
Clarification of Rumor or Report — Pending8-KDART
Mon 24 Aug 2026
Material Information for Investment Decisions — CTP51
투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 한국 품목허가 신청)
8-KDART
Fri 21 Aug 2026
Insider Ownership Report4DART
Fri 14 Aug 2026
Semi-annual Report — 2026.0610-QDART
Other Disclosure
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
OtherDART
Mon 03 Aug 2026
Material Information for Investment Decisions — CTP44
투자판단관련주요경영사항 (CTP44(다잘렉스 바이오시밀러) 한국 임상 3상 시험계획 변경신청)
8-KDART
Beneficial Ownership Report (5%) — Short FormSC 13D/GDART
Fri 31 Jul 2026
Insider Ownership Report4DART
Insider Ownership Report4DART
Insider Ownership Report4DART
Insider Ownership Report4DART
Insider Ownership Report4DART
Thu 30 Jul 2026
Material Information for Investment Decisions — CTP55
투자판단관련주요경영사항 (CTP55(코센틱스 바이오시밀러) 미국 품목허가 신청)
8-KDART
Mon 27 Jul 2026
[Amendment] Preliminary Consolidated Operating Results (Fair Disclosure)8-K/ADART